Excerpt:
… San Francisco-based Herophilus created organoids to model the rare disorder Rett syndrome and used them to screen for compounds that turn on a gene that is silenced in patients with the neurological condition, said co-founder and Chief Executive Saul Kato. Herophilus, whose investors include 515 Ventures, aims to launch clinical trials next year, Dr. Kato said.